Publications by authors named "Lynne S Brunner"
Objective: To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the treatment of bacterial conjunctivitis.
View Article and Find Full Text PDFArticle Synopsis
- Besifloxacin is a new fluoroquinolone antibiotic approved for treating eye infections, and its effectiveness was tested on 2,690 clinical isolates from 40 different species.
- It showed strong potency against gram-positive bacteria and anaerobes, outperforming other tested agents in this regard.
- Additionally, besifloxacin was as effective as other fluoroquinolones against most gram-negative bacteria, including those resistant to other antibiotic classes.
Background: Besifloxacin ophthalmic suspension 0.6% is a new topical fluoroquinolone for the treatment of bacterial conjunctivitis. Besifloxacin has potent in vitro activity against a broad spectrum of ocular pathogens, including drug-resistant strains.
View Article and Find Full Text PDFObjective: To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of vehicle in the treatment of bacterial conjunctivitis.
Research Design And Methods: This was a randomized, multicenter, double-masked, vehicle-controlled study.